PARP1 and breast carcinoma: DDR-targeted therapies are emerging as promising strategies for treating breast cancer, particularly triple-negative breast cancer, wherein overexpression of DNA repair proteins, such as PARP1 and replication protein A, might alter the sensitivity to chemotherapy and DDR inhibitors (Lee et al., 2020).